Dendritic cell vaccine - CreaGene

Drug Profile

Dendritic cell vaccine - CreaGene

Alternative Names: CreaVax-BC; CreaVax-HCC; CreaVax-HCC Inj.; CreaVax-PC; CreaVax-PC Inj.; CreaVax-RA Inj.; CreaVax-RCC; CreaVax-RCC Inj.; Dendritic cell vaccine for glioblastoma multiforme - CreaGene; Renal cell carcinoma vaccine - CreaGene/Dong-A

Latest Information Update: 17 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Creagene
  • Developer Dong-A ST; JW CreaGene
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase III Liver cancer
  • Phase II Rheumatoid arthritis
  • Phase I/II Glioblastoma; Prostate cancer

Most Recent Events

  • 02 Aug 2015 Phase I development for Prostate cancer is ongoing in South Korea
  • 09 Dec 2013 CreaGene initiates enrolment in the phase II IMMANUEL trial for Liver cancer in South Korea (KCT0000986)
  • 09 Aug 2013 Phase-II clinical trials in Rheumatoid arthritis (combination therapy) in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top